NASDAQ:GNFT Genfit (GNFT) Stock Price, News & Analysis $4.09 +0.04 (+0.99%) (As of 10:43 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Genfit Stock (NASDAQ:GNFT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genfit alerts:Sign Up Key Stats Today's Range$4.09▼$4.2450-Day Range$4.05▼$6.3752-Week Range$3.12▼$6.42Volume839 shsAverage Volume16,079 shsMarket Capitalization$204.46 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company OverviewGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Genfit Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks37th Percentile Overall ScoreGNFT MarketRank™: Genfit scored higher than 37% of companies evaluated by MarketBeat, and ranked 802nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGenfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenfit has only been the subject of 1 research reports in the past 90 days.Read more about Genfit's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genfit are expected to decrease in the coming year, from $0.98 to ($0.58) per share.Price to Book Value per Share RatioGenfit has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.13% of the float of Genfit has been sold short.Short Interest Ratio / Days to CoverGenfit has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Genfit has recently decreased by 0.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.13% of the float of Genfit has been sold short.Short Interest Ratio / Days to CoverGenfit has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Genfit has recently decreased by 0.79%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.93 News SentimentGenfit has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genfit this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Genfit is held by insiders.Percentage Held by InstitutionsOnly 2.24% of the stock of Genfit is held by institutions.Read more about Genfit's insider trading history. Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFT Stock News HeadlinesEuropean Equities Traded in the US as American Depositary Decline in Tuesday TradingNovember 26, 2024 | msn.comGenfit Balances Ipsen Partnership With High-Risk Pipeline AmbitionsNovember 21, 2024 | seekingalpha.comThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. December 3, 2024 | Porter & Company (Ad)GENFIT S.A.: GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting 2024November 17, 2024 | finanznachrichten.deGENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024November 13, 2024 | globenewswire.comGenfit’s Revenue Surge Driven by Key MilestoneNovember 8, 2024 | markets.businessinsider.comGENFIT Reports Third Quarter 2024 Financial InformationNovember 7, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Close Bearish Week on High Note FridayNovember 1, 2024 | msn.comSee More Headlines GNFT Stock Analysis - Frequently Asked Questions How have GNFT shares performed this year? Genfit's stock was trading at $3.85 at the beginning of the year. Since then, GNFT shares have increased by 6.2% and is now trading at $4.09. View the best growth stocks for 2024 here. When did Genfit IPO? Genfit (GNFT) raised $132 million in an initial public offering on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. How do I buy shares of Genfit? Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival Co. & (CCL). Company Calendar Today12/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNFT CUSIPN/A CIK1757064 Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+221.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.61 Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$41.31 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book2.74Miscellaneous Outstanding Shares49,990,000Free Float47,893,000Market Cap$202.46 million OptionableNot Optionable Beta1.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:GNFT) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.